{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:55:10Z","timestamp":1790564110271,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Brentuximab vedotin (BV)\u2010doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)\u2010AVD have transformed the frontline treatment of advanced\u2010stage Hodgkin lymphoma (HL), yet real\u2010world comparative data remain limited. In this multicentre retrospective study across 17 US centres, 646 patients treated between September 2011 and April 2025 were included; 509 (78.8%) received BV\u2010AVD and 137 (21.2%) received N\u2010AVD. Dose reductions or omissions were more common with BV\u2010AVD (35.8% vs. 14.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). N\u2010AVD was associated with higher rates of neutropenia (any grade 77.2% vs. 43.9%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001; grade \u22653 58.1% vs. 34.0%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) and infections (31.9% vs. 19.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004), while grade \u22653 infections and febrile neutropenia were comparable. Neuropathy was significantly more frequent with BV\u2010AVD (57.2% vs. 20.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). End\u2010of\u2010therapy complete response rates were numerically higher with N\u2010AVD (86.2% vs. 79.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.11). With a median follow\u2010up of 26.8\u2009months, 2\u2010year overall survival (OS) was 97% for BV\u2010AVD and 100% for N\u2010AVD (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.08) and 2\u2010year progression\u2010free survival (PFS) was 84% vs. 88% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.06). Survival outcomes were consistent in a 1:1 propensity score\u2010matched cohort. These real\u2010world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N\u2010AVD as a frontline standard for advanced\u2010stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70854","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:06:51Z","timestamp":1790561211000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010world outcomes of nivolumab\u2010\n                    <scp>AVD<\/scp>\n                    and brentuximab vedotin\u2010\n                    <scp>AVD<\/scp>\n                    in paediatric and adult advanced\u2010stage Hodgkin lymphoma"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8052-5445","authenticated-orcid":false,"given":"Karan L.","family":"Chohan","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Cochran","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7444-4837","authenticated-orcid":false,"given":"Maya","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center New York University Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy","family":"Isenalumhe","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-2801","authenticated-orcid":false,"given":"Elif","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-2998","authenticated-orcid":false,"given":"Seo\u2010Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Rush University Medical Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Tiger","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-5883","authenticated-orcid":false,"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2423-0182","authenticated-orcid":false,"given":"Hayley","family":"Flanagan","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Castellino","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-2411","authenticated-orcid":false,"given":"Jonathan D.","family":"Bender","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhamani","family":"Kannaiyan","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-6794","authenticated-orcid":false,"given":"Justin","family":"Kahla","sequence":"additional","affiliation":[{"name":"University of Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Paige","family":"DePriest","sequence":"additional","affiliation":[{"name":"Duke University  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Narvel","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-0857","authenticated-orcid":false,"given":"Mallorie B.","family":"Heneghan","sequence":"additional","affiliation":[{"name":"University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0072-8603","authenticated-orcid":false,"given":"Samanta","family":"Catueno","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tobon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0694-266X","authenticated-orcid":false,"given":"Julia","family":"Fadul","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Faulkenberry","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ayers","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4265","authenticated-orcid":false,"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[{"name":"Rush University Medical Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmaan","family":"Mubeen","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-9355","authenticated-orcid":false,"given":"Jamie","family":"Flerlage","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8589-1804","authenticated-orcid":false,"given":"Robin E.","family":"Norris","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-3067","authenticated-orcid":false,"given":"Olivia","family":"Tran","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-0408","authenticated-orcid":false,"given":"Chalothorn","family":"Wannaphut","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Hawk","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-2267","authenticated-orcid":false,"given":"Miriam B.","family":"Garcia","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"},{"name":"Memorial Hermann Health System  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-2244","authenticated-orcid":false,"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riedell","sequence":"additional","affiliation":[{"name":"University of Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris M.","family":"Mahadeo","sequence":"additional","affiliation":[{"name":"Duke University  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center New York University Langone Health  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang J","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk\u2010stratification, and management","volume":"99","author":"Ansell SM","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433502","article-title":"Paradigm shifts in Hodgkin lymphoma treatment: from frontline therapies to relapsed disease","volume":"44","author":"Burton C","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna G","year":"1975","journal-title":"Cancer"},{"issue":"16","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1200\/JCO.2024.42.16_suppl.7053","article-title":"Seven\u2010year overall survival analysis from ECHELON\u20101 study of a+AVD versus ABVD in patients with previously untreated stage III\/IV classical Hodgkin lymphoma","volume":"42","author":"Ansell SM","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced\u2010stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera AF","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell SM","year":"2022","journal-title":"N Engl J Med"},{"issue":"34","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real\u2010world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim HS","year":"2018","journal-title":"J Korean Med Sci"},{"issue":"16","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized trials vs real\u2010world evidence: how can both inform decision\u2010making?","volume":"329","author":"Sheldrick RC","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington SF","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"27","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non\u2010Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_10_13_1","first-page":"90","article-title":"Using the common terminology criteria for adverse events (CTCAE\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites\u2010Martinez A","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"30","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential Brentuximab Vedotin and doxorubicin, vinblastine, and Dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens AM","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman E","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041063","article-title":"FDG\u2010PET\/CT in the monitoring of lymphoma immunotherapy response: current status and future prospects","volume":"15","author":"Al\u2010Ibraheem A","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors JM","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_2_10_18_1","article-title":"Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: a real\u2010world analysis from 20 US centers","volume":"10","author":"Bock AM","year":"2026","journal-title":"Hema"},{"issue":"6","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2022.282115","article-title":"End\u2010of\u2010treatment PET in early\u2010stage Hodgkin lymphoma: valuable in addition to interim PET","volume":"108","author":"Chohan KL","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false\u2010positive lesions at interim and end\u2010of\u2010treatment FDG\u2010PET in lymphoma as determined by histology: systematic review and meta\u2010analysis","volume":"85","author":"Adams HJA","year":"2016","journal-title":"Eur J Radiol"},{"issue":"1","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2025-1851","article-title":"Interim and end\u2010of\u2010treatment FDG\u2010PET demonstrate limited ability to predict 3\u2010year progression\u2010free survival with nivolumab\u2010AVD in first\u2010line treatment of advanced stage Hodgkin lymphoma: imaging sub\u2010analysis of phase 3 S1826 study","volume":"146","author":"Bartlett N","year":"2025","journal-title":"Blood"},{"issue":"10","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa MC","year":"2025","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2025-351","article-title":"Circulating tumor DNA analyses of molecular tumor burden are superior to PET\u2010assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826","volume":"146","author":"Paczkowska J","year":"2025","journal-title":"Blood"},{"issue":"24","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1182\/bloodadvances.2023010700","article-title":"Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced\u2010stage Hodgkin lymphoma","volume":"7","author":"Steiner RE","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1182\/bloodadvances.2023010622","article-title":"Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort","volume":"7","author":"Bowers JT","year":"2023","journal-title":"Blood Adv"},{"issue":"28","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith TJ","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte\u2010colony stimulating factor to reduce the incidence of chemotherapy\u2010induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro MS","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:06:55Z","timestamp":1790561215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":26,"alternative-id":["10.1111\/bjh.70854"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70854","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70854"}}